公开(公告)号：US20190231874A1

公开(公告)日：2019-08-01

申请号：US16196537

申请日：2018-11-20

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Avigdor SCHERZ ,  Yoram SALOMON ,  Arie MARCOVICH ,  Alexander BRANDIS ,  Daniel WAGNER

IPC: A61K41/00 ,  A61K31/407 ,  A61K47/36 ,  A61N5/06 ,  A61K31/555 ,  A61K47/18 ,  A61K31/519 ,  A61K9/00

CPC classification number: A61K41/0071 ,  A61K9/0048 ,  A61K31/407 ,  A61K31/519 ,  A61K31/555 ,  A61K47/186 ,  A61K47/36 ,  A61N5/062 ,  A61N2005/0659

Abstract: An ophthalmic composition is provided, comprising chlorophyll or bacteriochlorophyll compounds for photodynamic treatment (PDT) of diseases, disorders and conditions associated with corneal or scleral anomalies, such as corneal thinning and scleral stretching.

公开(公告)号：US20190125769A1

公开(公告)日：2019-05-02

申请号：US16092742

申请日：2017-04-10

Applicant: Yeda Research and Development Co. Ltd. ,  Memorial Sloan-Kettering Cancer Center

Inventor： Avigdor SCHERZ ,  Yoram SALOMON ,  LiIach AGEMY ,  Rachel HAMRI ,  Dina PREISE ,  Kwanghee KIM ,  Jonathan COLEMAN

IPC: A61K31/675 ,  A61K31/409 ,  A61K31/7068 ,  A61K31/7135 ,  A61P35/00

Abstract: An anti-myeloid-derived suppressor cells agent (“anti-MDSCs agent”) and a bacteriochlorophyll derivative (hereinafter “Bchl-D) for use in combination therapy for cancer, wherein the anti-MDSC agent and the Bchl-D are administered sequentially and the administration of the Bchl-D is followed by photodynamic therapy (PDT) or vascular targeted PDT (VTP).

公开(公告)号：US20220202838A1

公开(公告)日：2022-06-30

申请号：US17700063

申请日：2022-03-21

Applicant: YEDA RESEARCH AND DEVELOPMENT CO. LTD. ,  Memorial Sloan-Kettering Cancer Center

Inventor： Avigdor SCHERZ ,  Yoram SALOMON ,  Lilach AGEMY ,  Rachel HAMRI ,  Dina PREISE ,  Kwanghee KIM ,  Jonathan COLEMAN

IPC: A61K31/675 ,  A61K31/409 ,  A61K31/7068 ,  A61K31/7135 ,  A61K45/06 ,  A61P35/00

Abstract: An anti-myeloid-derived suppressor cells agent (“anti-MDSCs agent”) and a bacteriochlorophyll derivative (hereinafter”Bchl-D) for use in combination therapy for cancer. wherein the anti-MDSC agent and the Bchl-D are administered sequentially and the administration of the Bchl-D is followed by photodynamic therapy (PDT) or vascular targeted PDT (VTP).

公开(公告)号：US20130345417A1

公开(公告)日：2013-12-26

申请号：US13890126

申请日：2013-05-08

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Avigdor SCHERZ ,  Alexander Brandis ,  Ohad Mazor ,  Yoram Salomon ,  Hugo Scheer

IPC: C07F15/04

CPC classification number: A61N5/062 ,  A61F9/0008 ,  A61K31/40 ,  A61K41/0071 ,  A61K41/0076 ,  A61K49/0036 ,  A61N5/0624 ,  C07F1/08 ,  C07F3/02 ,  C07F3/06 ,  C07F13/005 ,  C07F15/006 ,  C07F15/0066 ,  C07F15/045

Abstract: The invention provides anionic water-soluble tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one, preferably two or three, negatively charged groups and/or acidic groups that are converted to negatively charged groups at the physiological pH, preferably Bchls having a group COO , COS , SO3 , PO3 , COOH, COSH, SO3H, and/or PO3H2 bound through an ester or amide bond to one or more of the positions 17 , 13 , and 3 of the tetracyclic or pentacyclic Bchl molecule, for photodynamic therapy and diagnosis.

公开(公告)号：US20160354468A1

公开(公告)日：2016-12-08

申请号：US15240221

申请日：2016-08-18

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Avigdor SCHERZ ,  Yoram SALOMON ,  Arie MARCOVICH ,  Alexander BRANDIS ,  Daniel WAGNER

IPC: A61K41/00 ,  A61K31/519 ,  A61N5/06 ,  A61K47/18 ,  A61K9/00 ,  A61K31/407 ,  A61K47/36

CPC classification number: A61K41/0071 ,  A61K9/0048 ,  A61K31/407 ,  A61K31/519 ,  A61K31/555 ,  A61K47/186 ,  A61K47/36 ,  A61N5/062 ,  A61N2005/0659

Abstract: An ophthalmic composition is provided, comprising chlorophyll or bacteriochlorophyll compounds for photodynamic treatment (PDT) of diseases, disorders and conditions associated with corneal or scleral anomalies, such as corneal thinning and scleral stretching.

Abstract translation: 提供了一种眼用组合物，其包含用于光动力学治疗（PDT）的叶绿素或细菌叶绿素化合物，所述疾病，病症和病症与角膜或巩膜异常相关，例如角膜变薄和巩膜拉伸。

公开(公告)号：US20140088293A1

公开(公告)日：2014-03-27

申请号：US14093562

申请日：2013-12-02

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Avigdor SCHERZ ,  Oksana Shlyk-Kerner ,  IIan Samish ,  David Kaftan ,  Jorge Dinamarca

IPC: C07K14/405

CPC classification number: C07K14/405 ,  C07K14/195

Abstract: An isolated polynucleotide is provided. The isolated polynucleotide comprising a nucleic acid sequence encoding a polypeptide of a Type II reaction center of a photosynthetic organism, the nucleic acid sequence being capable of imparting the type II reaction center with an activity under a temperature range different than that of the type II reaction center endogenous to the photosynthetic organism. Also provided are methods of using the sequences for generating photosynthetic organisms or tailor-made thermotolerance.

Abstract translation: 提供了分离的多核苷酸。 分离的多核苷酸包含编码光合生物的II型反应中心的多肽的核酸序列，所述核酸序列能够使II型反应中心在不同于II型反应的温度范围内具有活性 对光合生物体内生的中心。 还提供了使用序列产生光合生物或定制耐热性的方法。

公开(公告)号：US20210330792A1

公开(公告)日：2021-10-28

申请号：US17370743

申请日：2021-07-08

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Avigdor SCHERZ ,  Yoram SALOMON ,  Arie MARCOVICH ,  Alexander BRANDIS ,  Daniel WAGNER

IPC: A61K41/00 ,  A61K31/407 ,  A61K31/555 ,  A61K9/00 ,  A61K31/519 ,  A61K47/36 ,  A61N5/06

Abstract: An ophthalmic composition is provided, comprising chlorophyll or bacteriochlorophyll compounds for photodynamic treatment (PDT) of diseases, disorders and conditions associated with corneal or scleral anomalies, such as corneal thinning and scleral stretching.

公开(公告)号：US20210236638A1

公开(公告)日：2021-08-05

申请号：US17188988

申请日：2021-03-01

Applicant: Memorial Sloan Kettering Cancer Center ,  Yeda Research and Development Co., Ltd.

Inventor： Jonathan COLEMAN ,  Phillip A. WATSON ,  Kwanghee KIM ,  Avigdor SCHERZ

IPC: A61K41/00 ,  A61P35/00 ,  A61K31/4166 ,  A61K38/08 ,  A61K47/64

Abstract: A method for treatment of prostate cancer or benign prostate hyperplasia by combination therapy comprising administering to a patient an androgen-deprivation therapy agent and a bacteriochlorophyll derivative followed by photodynamic therapy (PDT) or vascular-targeted photodynamic therapy (VTP).

公开(公告)号：US20200094069A1

公开(公告)日：2020-03-26

申请号：US16397515

申请日：2019-04-29

Applicant: Yeda Research and Development Co. Ltd.

Inventor： Avigdor SCHERZ ,  Alexander BRANDIS ,  Ohad MAZOR ,  Yoram SALOMON ,  Hugo SCHEER

IPC: A61N5/06 ,  C07F15/00 ,  C07F13/00 ,  C07F3/06 ,  C07F3/02 ,  C07F1/08 ,  A61K41/00 ,  A61F9/00 ,  C07F15/04 ,  A61K49/00 ,  A61K31/40

Abstract: The invention provides anionic water-soluble tetracyclic and pentacyclic bacteriochlorophyll derivatives (Bchls) containing at least one, preferably two or three, negatively charged groups and/or acidic groups that are converted to negatively charged groups at the physiological pH, preferably Bchls having a group COO , COS , SO3 , PO3 , COOH, COSH, SO3H, and/or PO3H2 bound through an ester or amide bond to one or more of the positions 17 , 13 , and 3 of the tetracyclic or pentacyclic Bchl molecule, for photodynamic therapy and diagnosis.

公开(公告)号：US20180296675A1

公开(公告)日：2018-10-18

申请号：US15924039

申请日：2018-03-16

Applicant: Memorial Sloan Kettering Cancer Center ,  Yeda Research and Development Co., Ltd. at the Weizmann Institute of Science

Inventor： Jonathan COLEMAN ,  Philip A. WATSON ,  Kwanghee KIM ,  Avigdor SCHERZ

IPC: A61K41/00 ,  A61P35/00 ,  A61K38/08 ,  A61K31/4166 ,  A61N5/06

Abstract: A method for treatment of prostate cancer or benign prostate hyperplasia by combination therapy comprising administering to a patient an androgen-deprivation therapy agent and a bacteriochlorophyll derivative followed by photodynamic therapy (PDT) or vascular-targeted photodynamic therapy (VTP).